The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND:The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system).
METHODS:This phase 1/2 study...
BACKGROUND:The number of patients aged ≥75 years who present with a stage I nonsmall cell lung cancer (NSCLC) is increasing. Elderly patients often have significant comorbidity and may be unfit for surgery. Furthermore, surgery in the elderly is associated with increased mortality and morbidity. In this study, the authors evaluated the outcomes of stereotactic radiotherapy (SRT) in elderly patients...
BACKGROUND:Several reports have revealed the association between single nucleotide polymorphisms (SNPs) and the development of cancer. Although many SNPs have been investigated, they were tested individually. In this study, nonsynonymous SNPs present in DNA damage response genes were comprehensively analyzed for lung cancer susceptibility.
METHODS:The authors selected 37 nonsynonymous SNPs in 23...
BACKGROUND:The core strategy of American College of Chest Physicians lung cancer guidelines is identification of the earliest symptoms of lung cancer and the immediate initiation of diagnosis and treatment. In the absence of screening, most symptomatic lung cancer is discovered at advanced stages, with the goal of long‐term survival entirely dependent on effective treatment of stage III and IV lung...
BACKGROUND:Because of their proximity to the pulmonary artery or vein, hilar lymph nodes are routinely biopsied with endobronchial or endoscopic ultrasonography (EUS)‐guided fine‐needle aspiration biopsy (FNAB). Computed tomography (CT)‐guided percutaneous needle biopsy (PNB) allows the operator to acquire a larger core needle biopsy (CNB) when initial samples are inconclusive, when the suspected...
BACKGROUND:Determine the effects of race, socioeconomic status, and treatment on outcomes for patients diagnosed with lung cancer.
METHODS:The Florida cancer registry and inpatient and ambulatory data were queried for patients diagnosed from 1998‐2002.
RESULTS:A total 76,086 of lung cancer patients were identified. Overall, 55.6% were male and 44.4% were female. The demographic distribution of patients...
BACKGROUND:In extensive‐stage small cell lung cancer (SCLC), the combination of pemetrexed plus carboplatin has shown activity and appeared to be well‐tolerated. We conducted a trial to confirm the efficacy and to assess the tolerability of this chemotherapy combination.
METHODS:Patients with untreated extensive‐stage SCLC were enrolled in this phase 2 open‐labeled study. They receive pemetrexed...
BACKGROUND:The objective of this study was to examine the effects of different definitions of local recurrence on the reported patterns of failure and associated risk factors in patients who undergo potentially curative resection for stage I nonsmall cell lung cancer (NSCLC).
METHODS:The study included 306 consecutive patients who were treated from 2000 to 2005 without radiotherapy. Local recurrence...
BACKGROUND:The malignant biological behavior of small‐sized lung adenocarcinomas remains obscure, although understanding this feature is important for selecting appropriate treatment. In the current study, the authors evaluated malignancy grades of small adenocarcinomas using fluorodeoxyglucose‐positron emission tomography/computed tomography (PET/CT) in addition to high‐resolution CT (HRCT) and pathological...
BACKGROUND:Recent genome‐wide association studies of lung cancer have shown that the CHRNA5‐A3 region on chromosome 15q24‐25.1 is strongly associated with an increased risk of lung cancer and nicotine dependence, and is thought to be associated with chronic obstructive pulmonary disease as well. However, it has not been established whether the association between genetic variants and lung cancer risk...
BACKGROUND:Nonsmall cell lung cancer (NSCLC) is the major determinant of overall cancer mortality worldwide. Despite progress in molecular research, current treatments offer limited benefits. Because NSCLC generates early metastasis, and this behavior requires great cell motility, herein the authors assessed the potential value of CFL1 gene (main member of the invasion/metastasis pathway) as a prognostic...
BACKGROUND:Treatment of older cancer patients at the end of life has become increasingly aggressive, despite the absence of evidence for better outcomes. We compared aggressiveness of end‐of‐life care of older metastatic cancer patients treated in the Veterans Health Administration (VHA) and those under fee‐for‐service Medicare arrangements.
METHODS:Using propensity score methods, we matched 2913...
BACKGROUND:Previous research has demonstrated that many lung cancer survivors report difficulties with symptom control and experience a poor quality of life (QOL). Although recent studies have suggested a relationship of single nucleotide polymorphisms (SNPs) in several cytokine genes with cancer susceptibility and prognosis, associations with symptom burden and QOL have not been examined. The current...
BACKGROUND:It has been demonstrated that NK012, a novel 7‐ethyl‐10‐hydroxycamptothecin (SN‐38)‐incorporating polymeric micelle, exerts significantly more potent antitumor activity against various human tumor xenografts than irinotecan (CPT‐11) (a water‐soluble prodrug of SN‐38). Combination therapy of anticancer agents with bevacizumab (Bv), an anti‐vascualr endothelial growth factor humanized monoclonal...
BACKGROUND:Identifying strong markers of prognosis is critical to optimize treatment and survival outcomes in patients with nonsmall cell lung cancer (NSCLC). The authors investigated the prognostic significance of preoperative cardiorespiratory fitness (peak oxygen consumption [VO2peak]) among operable candidates with NSCLC.
METHODS:By using a prospective design, 398 patients with potentially resectable...
BACKGROUND:Studies of lung cancer disparities between American Indians and Alaska Natives (AIANs) and whites have yielded mixed results. To the authors' knowledge, no studies to date have investigated whether race‐based differences in histology could explain survival disparities.
METHODS:Data were obtained on AIANs and whites with lung cancer from the 17 population‐based cancer registries participating...
BACKGROUND:To evaluate the benefits of lung cancer screening, all effects of screening need to be considered. The aim of this study was to determine whether screening had an effect on healthcare use, specifically whether use increased for those with a false‐positive or indeterminate screening result.
METHODS:Recruited were 400 individuals participating in a lung cancer screening study at the University...
BACKGROUND:The authors studied growth and progression of untreated nonsmall cell lung cancer (NSCLC) by comparing diagnostic and radiotherapy (RT) planning fluorodeoxyglucose (FDG)‐positron emission tomography (PET)/computed tomography (CT) scans before proposed radical chemo‐RT.
METHODS:Patients enrolled on a prospective clinical trial were eligible for this analysis if they underwent 2 pretreatment...
BACKGROUND:Disparities in care have been documented for foreign‐born cancer patients in the United States. However, few data are available regarding patients with lung and colorectal cancer. In the current study, the authors assessed whether patient‐reported quality and receipt of recommended care differed between US‐born and foreign‐born cancer patients.
METHODS:The authors collected surveys and...
BACKGROUND:The current study was conducted to assess the efficacy and toxicity of sorafenib as front‐line therapy in patients with stage IIIB (pleural effusion) or IV nonsmall cell lung cancer (NSCLC).
METHODS:Patients received sorafenib 400 mg twice daily by mouth continuously, and were evaluated every 2 weeks during the first 8 weeks. Patients who manifested clinical progression during this period...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.